文献速递中医内科中药与中成药合理使用

中药注射剂治疗重症肺炎疗效比较:系统评价与贝叶斯网络Meta分析

Comparative Efficacy of Chinese Herbal Injections for Treating Severe Pneumonia: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Front Pharmacol · 2022-01-10

该系统评价与贝叶斯网络Meta分析检索7个数据库至2021年4月1日,纳入64项RCT共5904例重症肺炎患者,比较6种中药注射剂联合西医常规治疗的疗效。结果显示血必净、痰热清、热毒宁、参麦联合西医常规治疗在提高临床有效率方面优于单用西医常规治疗,其中痰热清联合西医常规治疗改善临床有效率排名最高。

要点

  • 痰热清联合西医常规治疗在提高临床有效率方面SUCRA排名最高(66.4%)。
  • 血必净、痰热清、热毒宁、参麦联合西医常规治疗临床有效率优于单用西医常规治疗。
  • 仅不足30%的纳入研究(18项RCT)报告了不良反应/不良事件。

核心结论

  • 中药注射剂作为辅助治疗可能对重症肺炎患者有益。
  • 综合考虑临床有效率及其他结局,痰热清联合西医常规治疗在改善重症肺炎患者方面表现突出。

研究设计与样本

  • 系统评价与贝叶斯网络Meta分析,检索7个数据库至2021年4月1日。
  • 纳入64项随机对照试验,共5904例参与者。
  • 纳入6种中药注射剂:血必净、痰热清、热毒宁、喜炎平、参附、参麦。
  • 采用Cochrane偏倚风险工具评价方法学质量,OpenBUGS 3.2.3和STATA 14.0软件进行贝叶斯网络Meta分析。
  • 采用累积排序曲线下面积(SUCRA)概率值对治疗进行排序,并进行聚类分析比较两种不同结局的效应。

主要发现

  • 血必净联合西医常规治疗改善临床有效率优于单用西医常规治疗(OR=0.24,95%CI:0.19,0.30)。
  • 痰热清联合西医常规治疗改善临床有效率优于单用西医常规治疗(OR=0.22,95%CI:0.12,0.37)。
  • 热毒宁联合西医常规治疗改善临床有效率优于单用西医常规治疗(OR=0.29,95%CI:0.04,0.94)。
  • 参麦联合西医常规治疗改善临床有效率优于单用西医常规治疗(OR=0.27,95%CI:0.08,0.63)。
  • 基于SUCRA值,痰热清联合西医常规治疗在提高临床有效率方面排名最高(SUCRA:66.4%),在四项不同结局中排名第二,仅在一项结局中排名第三。

关键数值与推荐

  • 血必净联合西医常规治疗 vs 单用西医常规治疗:OR=0.24,95%CI:0.19,0.30。
  • 痰热清联合西医常规治疗 vs 单用西医常规治疗:OR=0.22,95%CI:0.12,0.37。
  • 热毒宁联合西医常规治疗 vs 单用西医常规治疗:OR=0.29,95%CI:0.04,0.94。
  • 参麦联合西医常规治疗 vs 单用西医常规治疗:OR=0.27,95%CI:0.08,0.63。
  • 痰热清联合西医常规治疗临床有效率SUCRA值为66.4%,排名最高。

临床怎么用

  • 重症肺炎患者可考虑在常规西医治疗基础上联合中药注射剂作为辅助治疗。
  • 痰热清联合西医常规治疗在提高临床有效率方面可能具有较好优势,可作为优先选择的辅助方案之一。
  • 临床决策时应结合患者具体情况及安全性信息,注意不良反应监测。

局限性

  • 仅不足30%的纳入研究(18项RCT)报告了不良反应/不良事件,安全性数据有限。
  • 研究检索截止至2021年4月1日,未纳入此后发表的研究。
  • 纳入研究的方法学质量通过Cochrane偏倚风险工具评价,但原文未报告具体偏倚风险分布。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Severe pneumonia (SP) has a high mortality rate and is responsible for significant healthcare costs. Chinese herbal injections (CHIs) have been widely used in China as a novel and promising treatment option for SP. Therefore, this study assessed and ranked the effectiveness of CHIs to provide more sights for the selection of SP treatment. Method: Seven databases were searched from their inception up to April 1, 2021. The methodological quality of included study was evaluated by the Cochrane risk-of-bias tool. Then, a Bayesian network meta-analysis (NMA) was performed by OpenBUGS 3.2.3 and STATA 14.0 software. The surface under the cumulative ranking curve (SUCRA) probability values were applied to rank the examined treatments. A clustering analysis was utilized to compare the effect of CHIs between two different outcomes. Results: A total of 64 eligible randomized controlled trials (RCTs) involving 5,904 participants were identified for this analysis. Six CHIs including Xuebijing injection (XBJ), Tanreqing injection (TRQ), Reduning injection (RDN), Xiyanping injection (XYP), Shenfu injection (SF), and Shenmai injection (SM) were included. The results of the NMA showed that XBJ [odds ratio (OR) = 0.24, 95% credible interval (CI): 0.19, 0.30], TRQ (OR = 0.22, 95% CI: 0.12, 0.37), RDN (OR = 0.29, 95% CI: 0.04, 0.94), and SM (OR = 0.27, 95% CI: 0.08, 0.63) combined with conventional Western medicine (WM) improved the clinical effective rate more significantly than WM alone. Based on SUCRA values, TRQ + WM (SUCRA: 66.4%) ranked the highest in improving the clinical effective rate, second in four different outcomes, and third in only one. According to the cluster analysis, TRQ + WM exerted a positive effect on improving the efficacy of SP. As for safety, less than 30% (18 RCTs) of the included studies reported adverse drug reactions/adverse drug events (ADRs/ADEs), including 14 RCTs of XBJ, 3 RCTs of TRQ, and 1 RCT of RDN. Conclusion: In conclusion, the study found that the CHIs as co-adjuvant therapy could be beneficial for patients with SP. TRQ + WM showed an outstanding improvement in patients with SP considering both the clinical effective rate and other outcomes. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/], identifier [CRD42021244587].

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Niu L, Xiao L, Zhang X, et al. Comparative Efficacy of Chinese Herbal Injections for Treating Severe Pneumonia: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2022. PMID: 35082663. doi:10.3389/fphar.2021.743486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。